Vigil Neuroscience, Inc. VIGL 深 沪
等待开盘 02-04 09:30:00 美东时间
8.05
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.05
- 总市值 3.76亿
- 52周最高 8.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.312
- 委 比 0.00%
- 总股本 4667.15万
- 历史最高 18.27
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.312
- 每 手 1
- 风险率 2.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Loss-Making Russell 2000 Stocks Drive Surprise Rally, Says Liz Ann Sonders
Liz Ann Sonders, the Chief Investment Strategist at Charles Schwab & Co. (NYSE: SCHW) highlighted certain unusual divergences in the small cap markets.
2025-10-10 16:27
Vigil Neuroscience Q2 EPS $(0.56) Misses $(0.42) Estimate
Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.42) by 32.08 percent. This is a 7.69 percent decrease over losses of $(0.52) per share
2025-08-05 21:37
Vigil Neuroscience Inc Merger and Leadership Changes
An update from Vigil Neuroscience Inc ( ($VIGL) ) is now available. On August 4...
2025-08-05 21:28
Vigil Neuroscience Faces Stockholder Demands Post-Merger
Vigil Neuroscience Inc ( ($VIGL) ) has issued an update. On May 21, 2025, Vigil...
2025-07-28 19:57
Vigil Neuroscience Awaits HSR Expiration for Sanofi Merger
Vigil Neuroscience Inc ( ($VIGL) ) has shared an announcement. On May 21, 2025,...
2025-07-17 19:27
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: TASK, VIGL, STRM, and CHTR
NEW YORK, July 3, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
2025-07-04 05:34
Vigil Neuroscience Announces Special Meeting for Sanofi Merger Vote
New activity is brewing for Vigil Neuroscience Inc ( ($VIGL) ). The company has...
2025-06-30 23:56
Vigil Neuroscience fails in mid-stage study for lead asset
Vigil Neuroscience (NASDAQ:VIGL) announced on Wednesday that a mid-stage trial for its lead candidate, iluzanebart, didn’t succeed in patients with a rare neurological disease called adult-onset leuko...
2025-06-04 19:26
Vigil Neuroscience Discontinues Phase 2 Extension Study For Iluzanebart After Trial Results
Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2
2025-06-04 19:16
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
Vigil Neuroscience announced that its Phase 2 IGNITE trial of iluzanebart for ALSP showed favorable safety and tolerability but no beneficial effects on clinical endpoints, leading to the discontinuation of the trial. The company expressed gratitude to the ALSP community and noted the trial contributed valuable insights into the disease.
2025-06-04 11:00
